SHILPA MEDICARE LTD
SHILPAMED · General/Diversified · NSE
₹547
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for SHILPAMED yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
Moderate
Confidence
29%
ROE
3.3%
Debt/Equity
0.25
WACC
11.1%
Market Cap
₹10,693 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
10.5%
Return on capital employed
EV / EBITDA
23.9×
Enterprise multiple
Debt / EBITDA
1.5×
Leverage vs earnings
Interest Coverage
3.4×
EBIT covers interest
Current Ratio
1.46×
Short-term liquidity
Asset Turnover
0.46×
Revenue per ₹ of assets
Revenue CAGR (3Y)
13.8%
3-year revenue growth
Revenue CAGR (5Y)
13.1%
5-year revenue growth
Ratio Trends
SHILPAMED · last 7 annual periods
ROE
3.3%
ROCE
10.5%
Operating Margin
—
Debt / Equity
0.25×
PE
128.4×
EV / EBITDA
40.9×
Historical Financials
SHILPAMED · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1140 Cr | ₹1043 Cr | ₹1152 Cr | ₹1286 Cr | ₹1539 Cr | +7.8% |
| EBITDA | ₹223 Cr | ₹113 Cr | ₹246 Cr | ₹348 Cr | ₹535 Cr | +24.4% |
| EBIT | ₹143 Cr | ₹24.2 Cr | ₹151 Cr | — | — | +1.3% |
| PAT | ₹60.7 Cr | ₹-32.5 Cr | ₹31.9 Cr | ₹78.3 Cr | ₹243 Cr | +41.5% |
| EPS (diluted) | ₹7.26 | ₹3.74 | ₹3.67 | — | — | -15.7% |
| CFO | ₹105 Cr | ₹180 Cr | ₹137 Cr | ₹132 Cr | ₹342 Cr | +34.3% |
| CapEx | ₹-332 Cr | ₹-227 Cr | ₹-185 Cr | ₹-244 Cr | ₹-371 Cr | — |
| FCF | ₹-227 Cr | ₹-46.7 Cr | ₹-47.9 Cr | ₹-111 Cr | ₹-28.4 Cr | — |
| Total Assets | ₹2875 Cr | ₹2904 Cr | ₹3093 Cr | ₹3311 Cr | ₹3706 Cr | +6.5% |
| Total Debt | ₹683 Cr | ₹798 Cr | ₹937 Cr | ₹588 Cr | ₹660 Cr | -0.9% |
| Shareholders' Equity | ₹1822 Cr | ₹1783 Cr | ₹1801 Cr | ₹2363 Cr | ₹2591 Cr | +9.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SHILPAMED vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
PGHL PGHL | — | — | Pending | 3.1% | — |
 AKUMS AKUMS | — | — | Pending | 7.7% | — |
SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
VIYASH VIYASH | — | — | Pending | 2.8% | — |
 STAR STRIDES PHARMA SCI LTD | +6.2%+6.6% upside | 56 | Near Fair Value | 20.0% | — |
Click a ticker to view its fair-value analysis.
Dividend History
7 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹1.60/sh
Last payout
2025-09-17
₹0.50
Peak payout
₹0.55
Trailing yield
0.09%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
Risk Analysis
Volatility & drawdown
Risk profile of SHILPAMED →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SHILPAMED →
Compare
Head-to-head with peers
Compare SHILPAMED side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SHILPAMEDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.